Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer

An estimated 284,000 Americans will be diagnosed with breast cancer in 2021. Of these individuals, 15–20% have basal-like triple-negative breast cancer (TNBC), which is known to be highly metastatic. Chemotherapy is standard of care for TNBC patients, but chemoresistance is a common clinical problem...

Descripción completa

Detalles Bibliográficos
Autores principales: Rashid, Narmeen S., Hairr, Nicole S., Murray, Graeme, Olex, Amy L., Leftwich, Tess J., Grible, Jacqueline M., Reed, Jason, Dozmorov, Mikhail G., Harrell, J. Chuck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512760/
https://www.ncbi.nlm.nih.gov/pubmed/34628286
http://dx.doi.org/10.1016/j.tranon.2021.101235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512760/
https://www.ncbi.nlm.nih.gov/pubmed/34628286
http://dx.doi.org/10.1016/j.tranon.2021.101235

Ejemplares similares